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A cDNA for procathepsin E was generated from human gastric adenocarcinoma (AGS) cells, amplified by PCR and inserted into the T7 dependent 
vector pET 22b for expression i E. coll. Purification of the resultant product was accomplished simply, without he need to resort to column 
chromatography. The recombinant protein displayed comparable properties to those of its naturally occurring counterpart. The yield of homoge- 
neous active enzyme obtained was - 3 mg per 40 g of cells. This is sufficient o permit crystallisation and structural analysis to begin and a 
mutagenesis programme to examine structure/activity relationships now to be undertaken. 
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1. INTRODUCTION 
The human body is known to contain five aspartic 
proteinases. Pepsin and gastricsin are both present in 
the stomach while the latter is also secreted from the 
prostate into seminal fluid [1,2]; renin is produced by a 
number of cells and tissues [3] while cathepsin D is a 
ubiquitous enzyme found in the lysosomes of most cells. 
The most recently characterised enzyme is cathepsin E
[4], which has been implicated in the biogenesis of the 
vasoconstrictor peptide, endothelin [5] and to have a 
possible role in enabling infection of cells by the human 
immunodeficiency virus [6]. Recently, it has also been 
identified, for the first time unequivocally, to be the 
enzyme responsible for processing of a defined antigen 
(ovalbumin) in a defined lymphocyte system [7]. 
All five enzymes are synthesised in the form of zymo- 
gens. Production (of the precursors) of the secretory 
enzymes, pepsin and renin, and the membrane-encapsu- 
lated lysosomal cathepsin D in recombinant form [8-10] 
has greatly facilitated investigations into structure/func- 
tion relationships in addition to providing sufficient ma- 
terial for 3-dimensional structural analysis by X-ray 
crystallography [11-13]. Cathepsin E is neither a secre- 
tory nor a lysosomal enzyme [7,14]; thus this intra- 
cellular aspartic proteinase is difficult to isolate in 
reasonable amounts. With its potential involvement in 
the processing reactions itemised above, it was consid- 
ered of interest o produce cathepsin E in recombinant 
form to facilitate its molecular characterisation. 
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2. MATERIALS AND METHODS 
The human gastric adenocarcinoma AGS cell line (ATCC Designa- 
tion, CRL 1739) which has been shown previously to express 
(pro)cathepsin E [15] was used as a source of total RNA. This was 
extracted using the lithium chloride precipitation based kit (RPN- 
1264, Amersham International plc, Bucks, UK). From this, messenger 
RNA was isolated using prepacked oligo(dT)-cellulose columns 
(Pharmacia Biotech. Ltd., Milton Keynes, UK) and cDNA was syn- 
thesised from 2/lg of mRNA using the cDNA Synthesis System Plus 
kit (Amersham International p c, Bucks, UK). Specific amplification 
of the procathepsin E cDNA was achieved using the PCR strategy 
described previously [l6] utilising sense and antisense primers derived 
from the 5'-untranslated and 3'-coding regions of the human pro- 
cathepsin E gene [15]. To facilitate cloning, these oligonucleotides 
(5'-GCGAGCATGCCATGGGATCCCTTCACAGGGTG-3') and 
(5'-CACCGGTCGACTTAGGGGACTGCTGGGGC-3") were de- 
signed to include NeoI and SalI restriction sites respectively. Extrac- 
tion and purification of the resulting 1,100 bp fragment and authenti- 
cation of the oligonucleotide s quence by the dideoxy method was 
performed as described previously [16]. 
The NeoI SalI fragment spanning the coding sequence for pro- 
cathepsin E, was subcloned into the T7 expression vector pET 22b 
(AMS Biotech. Ltd., Witney, Oxon, UK) and expression studies were 
carried out in the E. coli strain BL21 (DE3) pLysS obtained from the 
same source. Small scale cultures (10 ml) were induced by the addition 
of 1 PTG (to 0.4 mM) and, at appropriate ime intervals, samples were 
removed and the medium was separated by centrifugation from the 
E. coli cells. The pelleted cells were resuspended in 50 mM Tris-HCl 
buffer, pH 7.2, containing 0.15 M NaCI (Buffer A) and lysed by one 
freez~thaw cycle followed by the addition of 1.25 mg lysozyme. The 
supernatant was separated from insoluble material by centrifugation 
at 16,000 xg for 30 min. The latter was washed in Buffer A, re- 
sedimented and then dissolved in 6 M urea in 100 mM Tris-HCl buffer, 
pH 8.0, containing l mM glycine, 1 mM EDTA and 50 mM mercap- 
toethanol (Buffer B), as described by Lin et al. [8]. 
Aliquots of medium, supernatant and urea-solubilised material 
were analysed by SDS-PAGE with visualisation by Coomassie blue 
staining and by Western blotting using a polyclonal antiserum raised 
against a synthetic peptide corresponding to the C-terminal sequence 
of the human enzyme (kindly provided by Dr. Anthony Davenport, 
University of Cambridge, UK). Proteolytic activity was measured 
against haemoglobin assubstrate [14] in 0.17 M sodium citrate buffer, 
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pH 3.1, when crude preparations eeded to be evaluated; orutilising 
peptide substrates containing p-nitrophenylalanine (Nph) in the P~ 
position as a chromogenic reporter group [17] when purer enzyme 
samples were available. Kinetic analyses with two of these peptide 
substrates (generously provided by Dr. Ben M. Dunn, University of 
Florida, USA) were performed as described previously [4] except that 
the pH used was pH 3.1 at a final ionic strength of 0.1 M. Initial 
velocities were measured with at least six concentrations of each pep- 
tide substrate within an appropriate range in order to derive the kinetic 
constants, K  I1 and Vm~x. The estimated rror for all measurements was 
always < 15%. Values for k~a, were derived from Vma X = k,.,, " [E] where 
the active concentration f individual preparations of enzyme was 
determined byactive site titration against pepstatin as described previ- 
ously [18]. The protein inhibitor from Ascaris lumbricoides and the 
synthetic inhibitor H-77 described previously [4,7,17], were kindly 
provided by Dr. R.J. Peanasky, University of South Dakota, USA and 
Dr. P.A. Charlton (formerly) of Glaxo, Greenford, UK, respectively. 
N-Terminal sequence analysis by Edman degradation was kindly 
performed by Dr. Benne Parten (University of Florida, Gainesville, 
FL, USA) using an ABI Model 470 A sequenator. 
3. RESULTS AND DISCUSSION 
Analysis of the cDNA obtained from the human 
AGS cell line as described in section 2 produced a nucle- 
otide sequence in precise ageement with that reported 
for human procathepsin E by Azuma et al. [15]. By 
means of the Nco I -Sa I I  ends engineered into the frag- 
ment, it was introduced thereby into a number of ex- 
pression vectors under the control of tac or IpL  pro- 
moters and attempts were made to produce recombi- 
nant  procathepsin E in E. coli,  either in its authentic 
form or as a fusion with such proteins as chlorampheni- 
col acetyl transferase and maltose-binding protein. In 
these preliminary experiments, little authentic material 
resulted, because of plasmid instabil ity/product toxicity 
in the E. col i  cells, and in the cases of the fusion con- 
structs, the resultant proteins accumulating in E. col i  
were completely insoluble, thus negating the advantage 
conferred by the presence of the fusion partner in pro- 
viding a simple affinity chromatography procedure to 
facilitate purification. 
On this basis, the necessity for a high yield expression 
system that was under very tight transcriptional control 
was indicated and, at this time, pET 22b, a supposedly 
secretory vector exhibiting just such characteristics, be- 
came available for use. In preliminary time course ex- 
periments on a 10 ml scale utilising cultures transformed 
with the pET 22b plasmid harbouring the procathepsin 
E gene, very little activity or immunoreactive material 
was detected in the medium or periplasmic space. How- 
ever, a strongly positive band at approximately 43 kDa 
was observed (Fig. 1), when whole cell lysates (prepared 
in SDS) were examined by Western blotting with the 
anti-cathepsin E antiserum. This reached a maximum 
two hours after addition of the IPTG inducer. Separa- 
tion of cell lysates into soluble and insoluble fractions 
indicated that the majority of the immunoreactive mate- 
rial was insoluble (Fig. 1). 
Consequently, for larger scale purification, cultures 
(8 litres) were induced and after 2 h, the cells were 
harvested and lysed. The insoluble material was recov- 
ered, washed with Buffer A and solubilised in the 6 M 
urea-containing Buffer B (see section 2). Previous re- 
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Fig. 1. SDS-PAGE of samples containing recombinant cathepsin E. 
(Upper panel) Lysate of E. coli cells harbouring the procathepsin 
E-containing plasmid (lane 1); soluble and insoluble fractions pre- 
pared therefrom (lanes 2 and 3, respectively); material obtained after 
pH 3.1 treatment, neutralisation a d centrifugation (lanes 4 and 5). 
SDS-PAGE was performed under educing conditions (in the presence 
of 100 mM mercaptoethanol) f r lanes 14 and under non-reducing 
conditions (in the absence ofmercaptoethanol) in lane 5. Visualisation 
after blotting onto nitrocellulose membrane was with an anti-cathep- 
sin E antiserum. (The band at - 65 kDa in lanes 1 and 3 is an E. coli 
component that cross-reacts with this antiserum; this band was ob- 
served also on blots of lysates from cells harbouring a control plasmid 
without the procathepsin E insert). (Lower panel) Aliquots of the 
urea-solubilised pellet, that had been diluted forty-fold and reconcen- 
trated, were analysed before (lane 6) and after (lane 7) acidification 
to pH 3.1 and re-neutralisation. SDS-PAGE gels were run under 
reducing conditions and stained with Coomassie blue. Mol. wt. mark- 
ers (kDa) migrated as indicated. 
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ports [8,10] have demonstrated that the homologous 
human (pro)enzymes, pepsinogen and procathepsin D, 
also accumulate in inclusion bodies in E. coli but dis- 
solve readily in 6 M urea and can be renatured there- 
from by forty-fold dilution of the denaturant. This pro- 
cedure was thus applied to the material solubilised by 
6 M urea and the resultant solution was then re-concen- 
trated by ultrafiltration in an Amicon stirred cell fitted 
with a PM-30 membrane. Proteolytic activity towards 
haemoglobin as substrate at pH 3.1 was readily meas- 
ured in the concentrate and since this was completely 
inhibited by inclusion of 100 nM pepstatin in the assays, 
it must be attributed to the action of an aspartic pro- 
teinase. Since E. coli is not known to produce this type 
ofproteinase, it would thus appear that active, recombi- 
nant (pro)cathepsin E had been generated. 
Numerous attempts were made to purify this material 
with potential activity by successive chromatographic 
procedures including DEAE-cellulose and FPLC on 
Mono Q. However, the (pro)cathepsin E was always 
eluted in comparable positions to the residual E. coli 
proteins. Therefore, a simpler procedure was devised. 
The partially-purified material, after solubilisation with 
6 M urea, re-folding by 40-fold dilution, and concentra- 
tion by ultrafiltration as described above, was acidified 
to pH 3.1 by the addition of 1 M sodium citrate buffer. 
After incubation for 10 rain at 25°C, the material was 
centrifuged and the supernatant was re-neutralised to 
pH 8.2. This solution was centrifuged again. Analysis 
of the resultant supernatant indicated that all of the 
activity (100%) towards haemoglobin as substrate had 
remained in solution, whereas all of the undesired pro- 
tein had precipitated and had been removed by centrif- 
ugation (Fig. 1; compare lanes 6 and 7). By this simple 
purification scheme, homogeneous material had been 
generated without the need to resort to column chrom- 
atography. 
Analysis by SDS-PAGE under reducing conditions, 
followed by staining with Coomassie blue revealed a 
single band of approximately 38 kDa (Fig. 1; lower 
panel). When the sample was electrophoresed under 
non-reducing conditions, bands of approximately 38 
and 76 kDa reacted positively on Western blots with the 
antiserum to cathepsin E (Fig. 1; upper panel). This 
tendency to form dimers linked by an inter-chain dis- 
ulphide bond has been observed previously for natu- 
rally-occurring cathepsin E. Samples of the con- 
centrated recombinant enzyme were sequenced after 
electroblotting onto PVDF membrane for direct intro- 
duction into the sequenator. Through 25 cycles, the 
following unique sequence was obtained: 
Thr-Glu-Ser-Cys-Met-Asp-Gln-Ser-Ala-Lys-Glu-Pro- 
Leu-Ile-Asn-Tyr-Leu-Asp-Met-Glu-Tyr-Phe-Gly-Thr -- 
This is exactly coincident with that predicted for mature 
cathepsin E from the nucleotide sequence [15]. Depend- 
ing on its source of origin (stomach or red blood cells), 
naturally-occurring, mature cathepsin E has been 
shown to be heterogeneous [19,20] at its N-terminus, 
consisting of two closely similar isozymes [4] which dif- 





It is evident that the acidification procedure used in 
the purification of the recombinant protein had resulted 
in activation of the 43 kDa proform to generate the 
shorter (38 kDa) of these two isozymes of mature 
cathepsin E in a homogeneous form. 
The concentration of active enzyme in each prepara- 
tion was determined by active site titration using isoval- 
eryl-pepstatin [18]. On this basis, it was estimated that 
the yield of homogeneous, active enzyme was approxi- 
mately 3,000 ¢tg from an 8 litre culture. This amount is 
substantially in excess of any material that can be puri- 
fied from naturally-occurring human cells or tissues. 
The ability of the recombinant enzyme to hydrolyse 
two chromogenic substrates was examined and kinetic 
parameters (Km, kcat) for their hydrolysis are listed in 
Table I. Both have been demonstrated previously to be 
excellent substrates for naturally-occurring cathepsin E
from both gastric and erythrocyte sources [4]. The val- 
ues derived for the recombinant enzyme were directly 
comparable to those kinetic parameters measured previ- 
ously for the naturally occurring enzymes. We have also 
shown previously that one feature which distinguishes 
cathepsin E from its lysosomal counterpart, cathepsin 
D, is its susceptibility to inhibition by a 17 kDa protein 
Table I
Kinetic constants for the interactions ofchromogenic substrates and 
inhibitors with recombinant human cathepsin E 
Substrate or inhibitor K~ K m kc~  
(nM) (uM) (s 1) 
1 65 120 
2 - 50 115 
Ascaris protein 5 - 
H-77 150 
Isovaleryl-pepstatin 0.3 
All measurements were carried out in 0.1 M sodium formate buffer, 
pH 3.1, at 37°C. 
Substrate 1 = Pro-Pro-Thr-Ile-Phe*Nph-Arg-Leu 
Substrate 2 =- Lys-Pro-Ile-Glu-Phe Nph-Arg-Leu 
The latter was used for evaluation of the inhibitors, which were all 
competitive in nature. The estimated precision of all values obtained 
was in the range 10 15%. 
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inhibitor from the parasit ic worm, Ascaris lumbricoides 
[4,7,14,18]. Consequently, an inhibit ion constant (Ki) 
was determined for the interaction of  this protein with 
the recombinant enzyme. The value obtained (Table I) 
was essentially identical to those determined previously 
[14,18] for natural ly-occurr ing cathepsin E from differ- 
ent tissues/cells/species. 
This comparabi l i ty  between the recombinant enzyme 
and its natural ly-occurr ing counterpart  was substanti-  
ated further by evaluation of  the interactions of  two low 
molecular weight inhibitors of  widely different poten- 
cies. The synthetic inhibitor H77 (= D-His-Pro-Phe-His- 
Leu-~[CHz-NH]-Leu-Val-Tyr) ,  which is much less 
potent han the Ascaris inhibitor, was comparab ly  effec- 
tive against he recombinant  enzyme (Table I) to the Ki 
reported earl ier against cathepsin E of  natural  origin 
[14]. Isovaleryl pepstat in was a very t ight-binding inhib- 
itor (Table I), as might be expected towards an aspartic 
proteinase, such as cathepsin E [14]. 
It would appear that the recombinant cathepsin E 
thus produced was comparable  in its behaviour to the 
enzyme isolated from natural  sources. The latter, how- 
ever, is notor ious for its heterogeneity: (a) at its N- 
terminus because of  the presence of  two scissile peptide 
bonds that are readily cleaved autocatalyt ical ly during 
activation of  the precursor under acidic condit ions [20]; 
(b) in being a glycoprotein [14,19]; (c) in having an 
'addi t ional '  cysteine residue (compared to other arche- 
typal aspartic proteinases) close to the N-terminus (res- 
idue 4) which forms an interchain disulphide bond so 
that an equi l ibr ium mixture of  monomer ic  and dimeric 
enzymes results. These facets, together with the paucity 
of  available material,  have not permitted crystal l isation 
and structural determinat ion to be undertaken so far. 
However, with this demonstrat ion of  the generation of  
large quantit ies of  homogeneous cathepsin E in, and its 
facile purif ication from E. coli, these two difficulties 
have been surmounted. A programme to replace the 
cysteine residue (with Ser) together with mutagenesis of  
other appropr iate  residues is now underway to address 
this situation and to enable evaluation of  structure/ 
function relationships in this important  enzyme. 
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